The retatrutide vs tirzepatide comparison answers one of the most-searched questions in the GLP-1 drug class. Tirzepatide is an FDA-approved dual agonist (GIP and GLP-1) prescribed for type 2 diabetes and weight management, marketed as Mounjaro and Zepbound. Retatrutide is an investigational triple agonist (GIP, GLP-1, and glucagon) currently in Phase 3 clinical trials, with topline data suggesting greater weight reduction outcomes.
Status: Triple Agonist vs Dual Agonist | Phase 3 vs FDA Approved | Research Use Only
Retatrutide vs Tirzepatide at a Glance
The retatrutide vs tirzepatide comparison comes down to four data points: approval status, receptor targets, weight reduction in trials, and Canadian access.
| Feature | Tirzepatide | Retatrutide |
| Approval Status | FDA approved (Mounjaro, Zepbound); Health Canada approved | Investigational; not approved by the FDA or Health Canada |
| Receptor Targets | Dual agonist: GIP + GLP-1 | Triple agonist: GIP + GLP-1 + Glucagon |
| Weight Reduction | 22.5% at 72 weeks (SURMOUNT-1, 15 mg) | 24.2% Phase 2; 28.7% TRIUMPH-4 Phase 3 (12 mg) |
| Trial Reference | SURMOUNT-1 (NEJM 2022) | NEJM 2023; TRIUMPH-4 (Dec 2025 topline) |
| Mechanism | Suppresses appetite, slows gastric emptying | Appetite + gastric emptying + energy expenditure |
| Common Adverse Events | Nausea, vomiting, diarrhea, constipation | Same plus dysesthesia and heart rate signals |
| Dosing | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Canadian Access (2026) | Yes (prescription) | No (clinical trial only) |
Bottom line: Tirzepatide is prescribable in Canada today. Retatrutide is not.
5 Key Differences Between Retatrutide and Tirzepatide
1. Approval Status
Tirzepatide is FDA-approved. Retatrutide is investigational.
- Tirzepatide: FDA approved 2022 (T2D) and 2023 (weight management); Health Canada approved as Mounjaro and Zepbound
- Retatrutide: still in Phase 3 trials, no regulatory submission as of April 2026
- Earliest possible FDA submission: 2027, pending TRIUMPH-1 readout
- Health Canada submission usually trails the FDA by 6 to 12 months for incretin drugs
Tirzepatide also picked up an obstructive sleep apnea indication in 2024 (Zepbound), expanding its on-label use beyond diabetes and weight. Retatrutide’s approval timeline depends on the seven remaining TRIUMPH readouts due in 2026, particularly TRIUMPH-1 (obesity), TRIUMPH-3 (cardiovascular outcomes), and TRIUMPH-5 (type 2 diabetes).
Compliance note: “grey market” retatrutide sold online bypasses standard manufacturing safeguards and is intended for lab use only. Health Canada has issued repeated advisories on unauthorized peptide imports, with multiple enforcement actions on file at recalls.canada.ca.
2. Receptor Targets
Tirzepatide hits two receptors. Retatrutide hits three.
- Tirzepatide (dual agonist): GLP-1 + GIP. Suppresses appetite, slows gastric emptying, supports glucose-dependent insulin secretion.
- Retatrutide (triple agonist): GLP-1 + GIP + glucagon. All of the above, plus increased energy expenditure and hepatic lipid mobilization.
The glucagon receptor is the differentiator. While glucagon typically raises blood glucose in fasting states, chronic low-level activation paired with GLP-1 produces a net metabolic effect that increases calorie burn and reduces liver fat.
The Sanyal et al. Nature Medicine 2024 MASLD substudy reported 82.4% mean liver fat reduction at 24 weeks on 12 mg retatrutide, with 86% of participants reaching normal liver fat content. No tirzepatide trial has matched that liver-specific outcome.
3. Weight Reduction Outcomes
Trial data show a clear step-up pattern as receptor activity increases.
| Compound | Receptors | Weight Reduction | Trial |
| Semaglutide | GLP-1 | 14.9% at 68 weeks | STEP-1, NEJM 2021 |
| Tirzepatide | GLP-1 + GIP | 22.5% at 72 weeks | SURMOUNT-1, NEJM 2022 |
| Retatrutide | GLP-1 + GIP + glucagon | 28.7% at 68 weeks | TRIUMPH-4, Dec 2025 |
The TRIUMPH-4 number is unprecedented. Participants on the 12 mg arm lost an average of 71.2 lbs from a baseline mean weight of 248.5 lbs at a baseline BMI of 40.4. More than half of the 12 mg arm lost at least 25% of body weight.
Direct head-to-head Phase 3 results between retatrutide and tirzepatide are expected in December 2026. The figures above come from separate trials with different populations, so they should not be read as a clean apples-to-apples comparison.
4. Dosing
Both are once-weekly subcutaneous injections.
- Tirzepatide: Single-dose pens and vials at 5 mg, 10 mg, or 15 mg weekly. Standard titration starts at 2.5 mg.
- Retatrutide (trials): 1 mg to 12 mg weekly. Highest weight reduction at 12 mg. Approved doses pending regulatory submission.
Tirzepatide’s titration schedule typically steps up every 4 weeks from 2.5 mg, allowing GI tolerance to develop before reaching the therapeutic 10 or 15 mg target. TRIUMPH-4 used a similar titration approach for retatrutide, starting participants at 2 mg with 4-week step-ups to the randomized target dose, then maintaining for the remainder of the 68-week treatment period.
5. Side Effects
Both share the GLP-1 class profile, but retatrutide trials show higher event rates.
Shared GI events: nausea, vomiting, diarrhea, constipation, reduced appetite.
Tirzepatide-specific warnings (FDA label):
- Boxed warning for thyroid C-cell tumors (animal data)
- Gallbladder problems, pancreatitis, and gastroparesis
- Hypoglycemia risk with insulin or sulfonylureas
Retatrutide-specific signals (TRIUMPH-4):
- Dysesthesia: 20.9% at 12 mg vs 0.7% placebo
- Discontinuation due to AEs: 18.2% at 12 mg vs 4% placebo
- Transient heart rate increases in some participants
How Retatrutide and Tirzepatide Work
Each compound activates a different mix of hormone receptors. Adding receptors has corresponded to bigger weight reduction outcomes.
Tirzepatide (GLP-1 + GIP)
- GLP-1 activation: Triggers insulin release, slows gastric emptying, and acts on hypothalamic appetite centres
- GIP activation: Supports insulin signaling, acts on adipose tissue, amplifies GLP-1’s appetite effect
The dual mechanism gave tirzepatide a stronger weight reduction profile than semaglutide in SURMOUNT-1.
Retatrutide (GLP-1 + GIP + glucagon)
GLP-1 and GIP function the same as tirzepatide. Glucagon receptor activation is the new pathway.
What glucagon adds:
- Increased energy expenditure (the body burns more calories at rest)
- Hepatic lipid mobilization (fat moves out of the liver)
- Liver fat oxidation (fat gets used as fuel)
Glucagon typically raises blood glucose, but the simultaneous GLP-1 activity offsets that effect. The net result is the metabolic signal investigators have been chasing for years: a drug that suppresses appetite, slows digestion, and burns more energy at the same time. This is why retatrutide produces both the highest weight reduction figures and the strongest liver fat reduction in any obesity trial published to date.
The trade-off is a broader systemic effect profile, which has translated into higher rates of certain adverse events compared with tirzepatide in indirect comparisons.
Clinical Trial Data: Retatrutide vs Tirzepatide
Tirzepatide has five completed SURMOUNT trials. Retatrutide has one Phase 3 readout so far, with seven more expected in 2026. The retatrutide vs tirzepatide evidence base will shift considerably this year.
Tirzepatide
- SURMOUNT-1 (NEJM 2022): 22.5% mean weight reduction at 72 weeks (15 mg, no T2D), with 91% of participants on 15 mg achieving ≥5% weight loss
- SURMOUNT-2: 14.7% reduction in adults with obesity + T2D
- SURMOUNT-3, -4, -5: Varied populations and durations, including post-intensive lifestyle intervention and Asia-Pacific cohorts
- Approvals: Mounjaro 2022 (T2D), Zepbound 2023 (weight), Zepbound 2024 (OSA)
The SURMOUNT program established the dual-agonist class as the new standard for incretin therapy, surpassing semaglutide’s STEP-1 results by roughly 7 percentage points at comparable durations.
Retatrutide
TRIUMPH-4 (topline Dec 11, 2025):
- 445 adults with obesity + knee osteoarthritis
- 28.7% body weight reduction at 68 weeks (12 mg)
- 26.4% at 9 mg dose
- WOMAC pain scores reduced up to 75.8%
- First Phase 3 readout of any triple agonist
Phase 2 (NEJM 2023, Jastreboff et al.):
- 338 adults with obesity, 48 weeks
- Dose-response across arms: 8.7% / 17.1% / 22.8% / 24.2% at 1/4/8/12 mg
- 100% of 12 mg participants achieved ≥5% reduction
MASLD substudy (Nature Medicine 2024):
- 82.4% mean liver fat reduction at 24 weeks
- 86% of participants reached normal liver fat content
- Strongest liver-specific result of any incretin trial to date
Seven additional Phase 3 trials read out in 2026. TRIUMPH-1 evaluates retatrutide in obesity (the primary indication for FDA submission), TRIUMPH-3 covers cardiovascular outcomes, and TRIUMPH-5 covers type 2 diabetes. The head-to-head trial against tirzepatide is expected in December 2026 and will produce the first within-trial comparison.
Availability in Canada (2026)
Tirzepatide is available by prescription. Retatrutide is not legally available outside of clinical trials. This is the most consequential split in the retatrutide vs tirzepatide comparison for Canadian patients.
Tirzepatide
Approved by Health Canada as Mounjaro (T2D) and Zepbound (weight management and OSA). Three access pathways:
- Physician prescription with verified medical indication
- Public or private drug coverage, where applicable
- Lilly’s patient support program (eligibility-based)
Cost varies by province, dose, and coverage. KwikPens and vials are sold via LillyDirect. Self-administration training is typically provided at the prescribing clinic or pharmacy at the first fill.
Retatrutide
Not approved by Health Canada or the FDA. Only authorized access is clinical trial participation. Canadians can:
- Search ClinicalTrials.gov for active retatrutide trials
- Check Health Canada’s clinical trial registry for site locations
- Consult a research-oriented physician about eligibility
Health Canada warning: Unapproved “research-only” peptides sold online are not authorized for human use. Vials from unverified sites have been the subject of multiple enforcement actions and have appeared in seizure data published on recalls.canada.ca.
Research-use sourcing: Compliant Canadian suppliers like Koi Peptides Canada provide batch-specific COA, HPLC purity verification (≥99%), mass spectrometry identity confirmation, and clear research-use-only labeling.
Side Effects and Safety Profile
Both compounds share the GLP-1 class adverse event profile. Retatrutide shows higher rates of dysesthesia and treatment discontinuation in Phase 3.
Shared GI events
- Nausea (most common, especially during dose escalation)
- Vomiting, diarrhea, constipation
- Reduced appetite, acid reflux
Most events are mild-to-moderate and resolve over 8 to 12 weeks. Slow titration reduces frequency. Clinical experience suggests patients who experience severe early symptoms often tolerate the drug after a brief pause and slower re-escalation.
Tirzepatide warnings (FDA label)
- Boxed warning: thyroid C-cell tumors (rodent data; not confirmed in humans)
- Gallbladder problems and gallstones
- Pancreatitis, gastroparesis
- Kidney damage with severe GI events (typically from dehydration)
- Hypoglycemia (with insulin or sulfonylurea combinations)
Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Tirzepatide’s safety database now includes millions of patient-years of prescribing data since 2022.
Retatrutide signals (TRIUMPH-4)
- Dysesthesia: 8.8% (9 mg), 20.9% (12 mg), 0.7% (placebo). Mostly mild, dose-dependent, and generally did not lead to discontinuation.
- AE discontinuation: 12.2% (9 mg), 18.2% (12 mg), 4% (placebo)
- Transient heart rate increases in some participants, consistent with glucagon receptor activation
The dysesthesia signal is the most distinctive new finding. Most cases were described as mild tingling or burning sensations, and the dose-dependent pattern is clear. Investigators are watching whether the signal persists across populations in the remaining TRIUMPH trials.
Full safety labeling is pending Phase 3 completion. The head-to-head retatrutide-vs-tirzepatide trial expected in December 2026 will produce the first direct comparative safety data.
Cost and Access in Canadian Healthcare
Tirzepatide costs hundreds of dollars per month without coverage. Retatrutide has no cash price because it cannot be sold.
Tirzepatide pricing
- Public coverage: Provincial formularies vary; Ontario, BC, Alberta, and Quebec each review separately. Mounjaro for T2D is more commonly covered than Zepbound for weight.
- Private insurance: Coverage depends on plan and indication, with weight coverage less common than diabetes coverage
- Cash price: Multi-hundred-dollar monthly cost without coverage
- LillyDirect: Published cash-pay options in some markets
- Patient support programs: May apply for eligible patients meeting financial criteria
Pricing also shifts between maintenance doses. The 15 mg strength typically costs more per month than starter doses, and provincial criteria sometimes require step therapy through lower doses first.
Retatrutide pricing
No Canadian cost structure exists. Trial participants access retatrutide at no cost as part of clinical research participation, with study sites covering administration and monitoring.
For research-use-only material, Canadian researchers should evaluate suppliers on documentation quality (COA, HPLC, mass spectrometry) rather than price. Unrealistically low pricing is a Health Canada-documented red flag, often associated with unverified manufacturing chains and counterfeit purity claims.
Frequently Asked Questions: Retatrutide vs Tirzepatide
Is retatrutide better than tirzepatide for weight loss?
Trial data show retatrutide produces greater mean weight reduction (28.7% Phase 3 vs 22.5% tirzepatide), but head-to-head results aren’t expected until December 2026. The current numbers come from separate trials with different populations. Individual responses also vary significantly.
Is retatrutide approved by the FDA or Health Canada?
No. Retatrutide is investigational and currently in Phase 3 clinical trials. Tirzepatide is approved by both the FDA (under Mounjaro for type 2 diabetes and Zepbound for weight management and OSA) and Health Canada.
What is the difference between retatrutide and tirzepatide?
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide’s glucagon receptor activation adds energy expenditure and liver fat mobilization to the mechanism, producing larger weight reduction figures in trials.
For a complete Canadian-context comparison with TRIUMPH-4 trial data and supplier documentation standards, see retatrutide vs tirzepatide research comparison.
Can my doctor prescribe retatrutide in Canada?
No. Retatrutide cannot be prescribed until Health Canada approval. The only authorized access is clinical trial participation through a registered TRIUMPH study site. Physicians can refer interested patients to active trials, but cannot supply the drug outside that context.
Are the side effects the same?
Both share GLP-1 class GI events (nausea, vomiting, diarrhea, constipation). Retatrutide trials reported higher overall AE frequency plus a dysesthesia signal (20.9% at 12 mg vs 0.7% placebo) and transient heart rate increases. Discontinuation rates were also higher in the 12 mg retatrutide arm.
When will retatrutide be approved?
Lilly’s TRIUMPH-1 obesity readout is expected in 2026. Regulatory submission could follow shortly after, with potential FDA approval in 2027 at the earliest. Health Canada approval typically trails FDA approval by 6 to 12 months for incretin drugs.
Is retatrutide the same as Mounjaro or Zepbound?
No. Mounjaro and Zepbound are brand names for tirzepatide. Retatrutide is a separate investigational compound from Eli Lilly with a triple-receptor profile and no brand name yet, as it has not been approved.
Should I buy retatrutide online?
Health Canada has issued repeated warnings against unauthorized peptide products sold online. Retatrutide is not approved for human use outside clinical trials, and unverified online sources carry safety, purity, and legal risks that have triggered multiple enforcement actions.
The Bottom Line
Only tirzepatide is available to Canadian patients today. The retatrutide vs tirzepatide question is a comparison between an approved therapeutic and an investigational research compound.
Tirzepatide is the approved dual agonist backed by the full SURMOUNT program and multiple regulatory approvals across the FDA and Health Canada. Patients with type 2 diabetes, weight management indications, or obstructive sleep apnea can access it through standard prescribing channels.
Retatrutide is the investigational triple agonist with the largest weight reduction figures published in any obesity trial. It has not been approved and cannot legally be prescribed in Canada. Seven more TRIUMPH readouts will be published across 2026, with the head-to-head trial against tirzepatide due in December 2026.
For research labs evaluating retatrutide, compliant sourcing matters more than price. Verified COA, HPLC purity, and mass spectrometry data are non-negotiable. The retatrutide vs tirzepatide comparison will look different a year from now. For today’s clinical decisions, tirzepatide is the only option on the table.
Disclaimer: This article is for informational purposes only and is intended for readers in research and scientific contexts. Retatrutide is an investigational compound not approved by Health Canada or the FDA for therapeutic use. Tirzepatide is FDA and Health Canada-approved as Mounjaro and Zepbound. Consult a licensed healthcare professional before any therapeutic decision.